Search Results

Biokin Pharmaceutical Co. Ltd., (“Biokin Pharma”) a leading pharmaceutical company with operations in China and U.S., and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport”), the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, today announced Cryoport’s full suite of temperature-controlled solutions will support Biokin Pharma’s pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China.

SystImmune Inc. has announced the creation of its Clinical Science Advisory Committee, appointing Dr. Hope Rugo, M.D., Dr. Sara Tolaney, M.D., M.P.H, Dr. Pasi Jänne, M.D., Ph.D., MMSC.

A recent report provides crucial insights along with application based and forecast information in the Global Parenteral Nutrition Medicament Market.

A recent report provides crucial insights along with application based and forecast information in the Global Basic Infusion Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market.

Systimmune Inc, a clinical-stage biopharmaceutical company developing multi-specific antibody therapies in oncology, today announces manufacturing development and production of a SARS-CoV-2 neutralizing protein SI-F019 at levels ready for preclinical testing.

SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs), announced the appointment of Martin Sebastian Olivo, M.D. as Chief Medical Officer, effective on February 7, 2022.

2U, Inc. announced that its partner, the University of Southern California (USC) Division of Biokinesiology and Physical Therapy, has welcomed 48 students to DPT@USC, USC’s new Hybrid Doctor of Physical Therapy (DPT) program.